- Home
- CYBN
CYBN
Cybin Inc.
as 12-18-2024 2:34pm EST
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The company is focused on advancing psychedelic-based therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions.
| Founded: | 2019 | Country: | Canada |
| Employees: | N/A | City: | N/A |
| Market Cap: | 207.5M | IPO Year: | N/A |
| Target Price: | $138.00 | AVG Volume (30 days): | 351.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.98 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.50 - $19.84 | Next Earning Date: | 02-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Cybin Inc. News
CYBN Breaking Stock News: Dive into CYBN Ticker-Specific Updates for Smart Investing
Business Wire
8 days ago
Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results
Business Wire
14 days ago
Cybin to Participate in Water Tower Research Fireside Chat on December 11, 2024
Business Wire
a month ago
Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder
Business Wire
a month ago
Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024
Business Wire
a month ago
Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results
Business Wire
2 months ago
Cybin to Participate at the 2024 Milken Institute Future of Health Summit
Business Wire
2 months ago
Cybin Announces Grant of First U.S. Composition of Matter Patent in Support of its CYB005 Phenethylamines Program
Business Wire
3 months ago
Cybin to Participate in Water Tower Research Fireside Chat on October 8, 2024
Compare CYBN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CYBN Cybin Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.